Myriad Genetics (MYGN) Asset Writedowns and Impairment (2009 - 2026)

Myriad Genetics has disclosed Asset Writedowns and Impairment across 17 years of filings, most recently posting $5.4 million for Q1 2026.

• In Q1 2026, Asset Writedowns and Impairment changed N/A year-over-year to $5.4 million; the TTM figure through Mar 2026 stood at $324.8 million (up 486.28% YoY), while the FY2025 annual figure was $319.4 million, up 464.31% from the prior year.
• Asset Writedowns and Impairment improved to $5.4 million in Q1 2026, from $2.7 million in the prior quarter.
• Over the last five years, Asset Writedowns and Impairment for MYGN reached as high as $316.7 million in Q2 2025 and fell as low as $800000.0 in Q3 2024.
• The 4-year median for Asset Writedowns and Impairment is $6.2 million (2022), against an average of $44.3 million.
• The widest YoY moves for Asset Writedowns and Impairment: up 2630.17% in 2025, down 93.72% in 2025.
• A 4-year view of Asset Writedowns and Impairment shows it stood at $6.2 million in 2022, then jumped by 593.55% to $43.0 million in 2024, then tumbled by 93.72% to $2.7 million in 2025, then jumped by 100.0% to $5.4 million in 2026.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $5.4 million, $2.7 million, and $316.7 million for Q1 2026, Q4 2025, and Q2 2025 respectively.